Skip to main content

Peer-review policy

Peer-review is the system used to assess the quality of a manuscript before it is published. Independent researchers in the relevant research area assess submitted manuscripts for originality, validity and significance to help editors determine whether the manuscript should be published in their journal. You can read more about the peer-review process here.



Clinical Proteomics operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous.

The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.

Manuscripts will be assigned to a handling Editor, who will appoint at least two referees. On receipt of their reports the handling Editor will make a recommendation to accept, to accept with minor revisions, to request major revisions and resubmission, or to reject. No manuscript will be rejected without being assessed by a member of the Editorial Board and one other expert.

Clinical Proteomics considers the following types of article: Letter to the Editor, Meeting report, Research, and Review. For more specific information, please take a look at our Submission Guidelines.

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 2.8
    5-year Journal Impact Factor: 3.9
    Source Normalized Impact per Paper (SNIP): 0.831
    SCImago Journal Rank (SJR): 1.015

    Speed 2023
    Submission to first editorial decision (median days): 10
    Submission to acceptance (median days): 159

    Usage 2023
    Downloads: 434,196
    Altmetric mentions: 385